Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Acquir Immune Defic Syndr
Main Authors: Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Wei, Xuelian, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, Fordyce, Marshall W.
Formato: Artigo
Idioma:Inglês
Publicado em: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804743/
https://ncbi.nlm.nih.gov/pubmed/26627107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000000908
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados